Boeing (BA) CEO says he expects large growth in demand for Defense business
Newsquawk Staff ·
Boeing (BA) CEO says he expects large growth in demand for Defense business.
What it means
Guidance-adjacent commentary from the chief executive sits in the category of management colour rather than hard disclosure: it moves the shares only when it diverges from what the last set of results and order-book data already implied. Boeing's defense segment has in past cycles been the offset to commercial volatility, with margins there historically pressured by fixed-price development contracts, so the operative question is whether 'large growth in demand' refers to volume of awards or to profitable volume, a distinction that has mattered in prior episodes where backlog grew while segment margins compressed. Demand language of this kind typically maps to government budget cycles and allied rearmament programmes rather than to anything Boeing controls, which makes the follow-ons the contract award flow, defense budget appropriations, and any update to segment margin guidance at the next results or investor event. CEO demand framing delivered outside a formal earnings setting has tended to be directional rather than quantified, and the precedent is that the market waits for the order book and the margin line to confirm it. Worth noting the peer read-across: defense primes have historically traded as a complex on budget and geopolitical demand signals, so commentary of this sort tends to be read against the whole contractor group rather than Boeing alone.
- Boeing (BA) says they will not reach the 737 production target of 47/month until 2027
- AMD (AMD) and Meta (META) collaborate across CPUs, GPUs, networking, systems and software to power Meta services and AI infrastructure; AMD will invest USD 1bln in Meta's equity offering
- Hilton (HLT) CEO says US middle-class real wages are growing despite higher inflation, contributing to broad-based strength in what management describes as a "C-shaped economy"
- US PRE-MARKET MOVERS: CDNS, GLW, SOFI, NVDA/META, PYPL, SPGI, WHR, RCL, SHW, UPS, JCI, BA, AVGO, MRNA
- Newsquawk Daily European Equity Opening News - 27th October 2026
Related headlines
- Apple (AAPL) introduces new 14-inch Macbook Pro with M6 chip, starts at USD 1,999; also introduces iMac with M6 chip delivering a major boost in performance and AI capabilities53 min ago
- ServiceNow (NOW) and Google (GOOGL) Cloud advance agentic Ai for industry workflows55 min ago
- Anduril and Qualcomm (QCOM) unveil blue-chip to rebuild American computer manufacturing; Anduril to start taking orders for blue-chip laptops in 202755 min ago
- UPS (UPS) says Q4 US average daily volume to be lower Y/Y and Q4 volume decline reflects planned reductions in Amazon (AMZN) business1 hour ago
- AbbVie (ABBV) announces the submission of a BLA for etentamig, following the positive phase 3 CERVINO study1 hour ago
- Freeport-McMoRan Inc. (FCX) Q3 2026 (USD): Adj. EPS 0.88 (exp. 0.82), Revenue 7.546bln (exp. 7.36bln).1 hour ago
- PACCAR Inc (PCAR) Q3 2026 (USD): EPS 1.61 (exp. 1.61), Revenue 7.94bln (exp. 7.54bln)1 hour ago
- US BROKER MOVES: AVGO upgraded at DA Davidson; MRNA downgraded at William Blair2 hours ago
- S&P Global Inc. (SPGI) Q3 2026 (USD): Adj. EPS 4.58 (exp. 4.43), Revenue 3.68bln (exp. 3.64bln); Co. is reviewing strategic options for Capital IQ and some of its data businesses2 hours ago
- PayPal Holdings Inc. (PYPL) Q3 2026 (USD): Adj. EPS 1.45 (exp. 1.31), Revenue 8.58bln (exp. 8.71bln); raises FY26 profit outlook2 hours ago
- Corning Incorporated (GLW) Q3 2026 (USD): Adj. EPS 0.91 (exp. 0.88), Core sales 5.08bln (exp. 5.03bln)2 hours ago
- Sherwin-Williams Company (SHW) Q3 2026 (USD): adj. EPS 3.63 (exp. 3.69), Revenue 6.86bln (exp. 6.78bln). Current FY adj. EPS 11.85-12.15 (exp. 12.09)2 hours ago
- Johnson Controls International (JCI) Q4 (USD) Adj. EPS 1.66 (exp. 1.58), Revenue 7.1bln (exp. 7.04bln), Next Qtr. EPS 1.15-1.20 (exp. 1.13)3 hours ago
- Coca-Cola Company (KO) Q3 2026 (USD): Adj. EPS 0.91 (exp. 0.88), Revenue 13.4bln (exp. 12.92bln)3 hours ago
- Pfizer's (PFE) Elrexfio demonstrated a clinically meaningful and statistically significant benefit for patients whose disease progressed after anti-CD38 therapy and lenalidomide in the Phase 3 MagnetisMM-32 trial3 hours ago